白藜芦醇苷通过抑制长链非编码RNA HULC表达抑制肝癌SMMC-7721和HepG2细胞的增殖和侵袭

原发性肝癌是临床上最常见的恶性肿瘤之一,目前仍在寻找有效的治疗手段。我们之前的研究证实白藜芦醇苷能够抑制肝癌细胞的增殖和侵袭,但其具体的分子生物学机制仍不清楚。本文主要探讨白藜芦醇苷调控肝癌细胞系SMMC-7721和HepG2肝癌细胞系增殖能力的分子生物学机制。首先,我们构建大鼠原发性肝癌模型,发现模型组肝组织中长链非编码RNA HULC的表达较正常组明显升高;同时检测白藜芦醇苷预防组（分为低剂量组,中剂量组和高剂量组）肝组织中肝癌细胞中出现异常的高表达(HULC)的表达情况。结果显示,在中、高剂量组中HULC的表达明显降低。在体外实验中,SMMC7721和HepG2中HULC的表达明显较正常肝组织显著增高,然而白藜芦醇苷高剂量组中HULC的表达发生明显降低,同时在SMMC7721和HepG2中加入白藜芦醇苷后,高剂量组中细胞增殖能力明显下降。为了进一步探究HULC在白藜芦醇苷预防肝癌中的功能,我们构建了HULC过表达质粒以及针对HULC的siRNA片段,并验证了过表达和敲低的效率。在使用高剂量白藜芦醇苷处理SMMC7721和HepG2的同时,过表达HULC能够逆转白藜芦醇苷引起的对细胞增殖的抑制,然而敲低HULC则能够更加有效地降低白藜芦醇苷对细胞增殖的抑制效果。这提示我们白藜芦醇苷能够可能通过调控HULC的表达抑制肝癌细胞的增殖和侵袭,二者具有协同作用。本文结果为预防原发性肝癌提供了新的理论依据但其临床疗效还需要进一步验证。     

利用免疫组织化学及蛋白质组学对树莓提取物抑制大鼠肝癌机制的研究

目的：探讨树莓预防大鼠原发性肝癌增殖抑制和凋亡诱导作用,寻找树莓预防大鼠原发性肝癌的特异性蛋白质靶点。方法：利用二乙基亚硝胺（DEN）建立大鼠原发性肝癌动物模型;通过免疫组织化学方法研究树莓提取物对于大鼠原发性肝癌的预防效果和形态学变化,利用蛋白质组学研究树莓预防大鼠原发性肝癌的特异性蛋白质靶点。结果：树莓提取物能抑制PCNAJVEGF的表达,抑制细胞增殖,并诱导细胞凋亡。蛋白质组学差异分析表明：成瘤组大鼠血清在蛋白质峰2597．93M／Z,4513．88M／Z上与高剂量树莓干预组大鼠血清具有显著性差异（P〈0．05）。结论：树莓提取物可以抑制肝癌细胞PCNA的表达,从而抑制肝癌细胞的增殖;还可以诱导肝癌细胞凋亡;蛋白质峰2597．93M／Z及4513．88M／Z所表达蛋白为其特异性作用靶点。     

白藜芦醇体外对肝癌HepG2细胞分化及P21WAF1/CIP1表达的影响

目的:探讨白藜芦醇(Resvratrol,Res)在体外对肝癌细胞分化及相关周期蛋白依赖激酶抑制因子P21WAF1/CIP1的影响.方法:体外培养肝癌HepG2细胞.用MTT法检白藜芦醇对HepG2细胞的生长抑制作用,用倒置显微镜观察肝癌细胞的形态改变,用放射免疫法检测其AFP分泌.以RT-PCR方法检测HepG2细胞中P21WAF1、CIP1mRNA的表达,用免疫细胞化学检测其P21WAF1、CIP1蛋白的表迭.结果:白藜芦醇呈时间剂量性抑制HepG2细胞株的增殖,使其亚细胞结构趋于正常,AFP分泌量下降,并显著上调HepG2细胞中P21WAF1/CIP1 mRNA和蛋白的表达.结论:白藜芦醇能诱导HepG2细胞在体外向正常肝细胞分化,并上调其P21WAF1/CIP1的表达.     

白藜芦醇体外对肝癌HepG2细胞分化及P21^WAF1/CIP1表达的影响

目的：探讨白藜芦醇（Resvratrol,Res）在体外对肝癌细胞分化及相关周期蛋白依赖激酶抑制因子P21^WAF1/CIP1的影响。方法：体外培养肝癌HepG2细胞,用MTT法检白藜芦醇对HepG2细胞的生长抑制作用,用倒置显微镜观察肝癌细胞的形态改变,用放射免疫法检测其AFP分泌,以RT-PCR方法检测HepG2细胞中P21^WAF1/CIP1mRNA的表达,用免疫细胞化学检测其P21^WAF1/CIP1蛋白的表达。结果：白藜芦醇呈时间剂量性抑制HepG2细胞株的增殖,使其亚细胞结构趋于正常,AFP分泌量下降,并显著上调HepG2细胞中P21^WAF1/CIP1mRNA和蛋白的表达。结论：白藜芦醇能诱导HepG2细胞在体外向正常肝细胞分化,并上调其P21^WAF1/CIP1的表达。     

MicroRNA-575靶向抑制BLID促进非小细胞肺癌细胞的增殖和侵袭

目的:通过体外实验探讨miR-575对非小细胞肺癌(NSCLC)细胞增殖与侵袭能力的影响及相关机制。方法:采用实时定量PCR法检测不同非小细胞肺癌细胞系中miR-575、BLID的表达;CCK-8法检测转染miR-575模拟物、抑制因子后不同时间A549细胞增殖情况的变化;Transwell法检测A549细胞的侵袭情况;Targetcan法及双荧光素酶检测miR-575对BLID 3'UTR端的靶向作用;Western blot法检测BLID蛋白的表达。结果:A549、SPC-A1、H1299、H1650等人非小细胞肺癌细胞系中miR-575的表达均显著高于永生化的人支气管上皮细胞系16HBE(P0.001)。MiR-575模拟物转染的A549细胞miR-575的表达明显高于对照组(P0.001),同时细胞的增殖和侵袭力增强(P0.05);反之,miR-575抑制因子转染的A549细胞miR-575的表达显著降低,且细胞的增殖和侵袭力明显降低(P0.01)。Targetscan法预测BLID可能是miR-575的下游靶基因,荧光素酶结果显示miR-575不仅能够有效抑制野生型BLID 3'UTR端的荧光素酶反应(P0.01),而且能够降低BLID的蛋白表达量(P0.01)。实时定量PCR结果显示BLID在NSCLC细胞系中均呈现显著的低表达(P0.001),且转染BLID后,NSCLC细胞的增殖和细胞侵袭被明显抑制(P0.05),而当miR-575与BLID共转染时,miR-575能够逆转BLID所抑制的细胞增殖和侵袭(P0.01)。结论:在NSCLC细胞系中,miR-575的表达上调,且能够通过直接作用于下游靶点抑癌基因BLID从而促非小细胞肺癌细胞增殖及侵袭。     

MiR-206与ANXA2的3′UTR靶向结合抑制乳腺癌侵袭

膜联蛋白A2（annexin A2,ANXA2）可促进人结直肠癌的侵袭和迁移。然而,ANXA2在乳腺癌中的作用以及调节机制尚缺乏系统的研究。本研究旨在探讨微小RNA-206（microRNA-206,miR-206）如何调节ANXA2基因的表达,进而影响乳腺癌的侵袭。通过基因预测软件TargetScan (TargetScan V5.2)找到与ANXA2的3′UTR区互补结合的miR-206。运用实时定量 PCR（qRT-PCR）检测不同乳腺癌细胞系中miR-206的表达水平,发现低侵袭性乳腺癌MCF-7细胞株miR-206 表达量明显高于高侵袭性乳腺癌细胞株MDA-231、MDA-435和T47D。运用转染技术将 miR-206 质粒及miR-206 抑制剂转入乳腺癌细胞系MDA-231后,qRT-PCR检测转染后各组细胞中miR-206的表达情况,结果显示转染成功。用Western印迹法检测各组细胞中ANXA2的表达情况,结果显示,miR-206负向调控ANXA2蛋白的表达。 qRT-PCR显示,过表达乳腺癌细胞内miR-206 后,ANXA2 mRNA基本没有变化。结果显示,miR-206是在翻译水平上影响ANXA2蛋白的表达。荧光素酶实验显示：miR-206能特异性地与ANXA2 mRNA的3′UTR结合,抑制其荧光素酶活性。Transwell侵袭实验检测各组细胞的侵袭能力。结果显示,过表达miR-206后,乳腺癌细胞体外侵袭能力明显减弱。综上所述,miR-206 通过靶向结合癌基因ANXA2 mRNA的3′UTR区,抑制ANXA2蛋白翻译,从而抑制了乳腺癌细胞的侵袭。因此,miR-206有望成为抑制乳腺癌侵袭与治疗乳腺癌的新靶点和生物学标记物。     

MicroRNA-21靶向调控β-catenin促进骨肉瘤细胞U2OS的增殖与侵袭

目的:研究微小RNA-21(microRNA-21,miR-21)对骨肉瘤细胞U2OS增殖与侵袭的影响及其可能机制。方法:采用Real-time PCR (RT-PCR)检测miR-21在骨肉瘤和临近正常骨组织中的表达差异。通过脂质体转染法将miR-21模拟物(microRNA-21mimics,即mimics组)及microRNA无关序列(microRNA-NC,即NC组)转染入骨肉瘤细胞U2OS,real-time PCR(RT-PCR)检测miR-21和β-catenin m RNA在U2OS细胞中的表达,Western blot检测β-catenin蛋白在U2OS细胞中的表达,并通过双荧光素酶报告基因验证miR-21与β-catenin基因3'-非编码区(3'-untranslated region,3'-UTR)的特异性结合作用。MTT法检测U2OS细胞体外增殖能力;Transwell侵袭模型探查U2OS细胞侵袭潜能。结果:骨肉瘤组织中miR-21水平显著高于正常骨组织(P0.05)。过表达miR-21能够增强细胞增殖与侵袭,上调U2OS细胞β-catenin m RNA和蛋白的表达。双荧光素酶报告基因结果表明miR-21可与β-catenin基因3'-UTR结合,从而对β-catenin的表达起调控作用。结论:miR-21可能通过调节β-catenin的表达促进骨肉瘤细胞U2OS的增殖与侵袭。     

MicroRNA-21反义寡核苷酸可以抑制U373MG细胞对替尼泊苷VM-26的耐受性

脑胶质瘤患者对化疗药物的耐受性是亟待解决的问题之一．microRNA参与了肿瘤发生发展的诸多过程．选取目前临床上常用的治疗脑恶性胶质瘤的化疗药物替尼泊苷(teniposide) VM-26和人恶性胶质瘤细胞系U373MG为研究对象,通过反义寡核苷酸技术,应用MTT及细胞生长曲线等方法,发现抑制microRNA-21的功能后,细胞活性明显降低,且可以在一定程度上抑制U373MG细胞对VM-26作用的耐受性,而且这种耐受性的抑制与细胞生长速度关系不大,从而为指导临床用药,探索肿瘤细胞耐受化疗药物的机制提供新的线索．     

白藜芦醇通过糖代谢重编程抑制DEN诱导大鼠肝细胞癌前阶段的恶性增殖

白藜芦醇(resveratrol,RES)可抑制肝癌细胞的生长与增殖。但其在癌前阶段的作用尚不十分清楚。本文研究白藜芦醇对二乙基亚硝胺(diethylinitrosamine, DEN)诱导大鼠肝癌前阶段的作用及机制。SD大鼠分为正常对照组、RES处理组、DEN处理组和RES-DEN处理组。研究结果表明,DEN处理大鼠8周时,肝细胞的总增殖细胞核抗原(proliferating cell nuclear antigen,PCNA)升高至2倍(P<0.05),核内PCNA蛋白表达水平升高至3倍(P<0.001),而RES-DEN处理组大鼠肝细胞总PCNA(P<0.05)和核内PCNA蛋白表达水平(P<0.001)降低。结果提示,RES可显著抑制肝细胞恶性增生。通过非靶向代谢物组学及代谢通路富集分析,结果表明,RES-DEN处理大鼠的肝细胞中,虽然磷酸戊糖途径向糖酵解途径的转变增强,但相较于DEN组大鼠,糖酵解水平并未出现显著提高,提示磷酸烯醇式丙酮酸-丙酮酸-乳酸这条代谢途径被抑制。进一步验证发现,这条代谢途径上的关键酶M2型丙酮酸激酶(M2-type pyruvate kinase,PKM2)和乳酸脱氢酶(lactate dehydrogenase,LDHA)蛋白质表达水平被抑制(P<0.05)。RES可通过调节糖代谢重编程,在肝癌的癌前阶段抑制DEN诱导的大鼠肝细胞的过度增殖,为RES预防肝癌提供了实验依据。     

microRNA-21 表达水平对新疆地区食管癌患者早期诊断及预后评估的临床价值

目的:探讨microRNA-21表达水平对新疆地区食管癌早期诊断及预后评估的临床价值。方法:收集我院收治的100例食管癌患者,其中哈萨克族患者50例,汉族患者50例,采用RT-PCR以及RT-qPCR的方法对患者血清microRNA-21表达水平进行检测并比较。结果:食管癌患者癌组织中microRNA-21表达水平均高于癌旁组织,差异具有统计学意义(P0.05);有淋巴结转移、ⅡB+Ⅲ期、低分化癌组织中的miRNA-21相对表达量高于无淋巴结转移、I+ⅡA期以及高分化癌组织患者,差异具有统计学意义(P0.05);miRNA-21在不同民族、性别、年龄分组中表达无明显差异(P0.05)。结论:microRNA-21表达水平对新疆地区食管癌患者癌组织中表达水平较高,在有淋巴转移、ⅡB+Ⅲ期以及低分化癌组织中表达水平较高,民族、性别以及年龄对microRNA-21水平的影响较小,因此microRNA-21检测对食管癌的早期诊断及预后判断具有指导意义。     

LncRNA GABPB1‑IT1 inhibits the tumorigenesis of renal cancer via the miR-21/PTEN axis

Long noncoding RNA (lncRNA) (GABPB1‑IT1) has been reported to be downregulated in lung cancer, while its expression and function in other cancers are unknown. In this study, the expression levels of GABPB1‑IT1 in tissue samples from 62 ccRCC patients were measured by performing RT-qPCR. Potential base pairing formed between GABPB1‑IT1 and miR-21 was explored using the online program IntaRNA 2.0 and further confirmed by Dual-luciferase activity assay and RNA pulldown assay. The role of GABPB1‑IT1 and miR-21 in regulating the expression of PTEN was evaluated by RT-qPCR and Western blot. The role of GABPB1‑IT1, miR-21, and PTEN in regulating the proliferation of Caki-2 cells was explored by CCK-8 assay. It was observed that GABPB1‑IT1 was downregulated in ccRCC and predicted poor survival. GABPB1‑IT1 directly interacted with miR-21, while it did not regulate the expression of each other. Moreover, upregulation of PTEN, which is a target of miR-21, was observed in ccRCC cells with overexpression of GABPB1‑IT1. Overexpression of GABPB1‑IT1 and PTEN decreased the proliferation rates of ccRCC cells. In addition, overexpression of GABPB1‑IT1 reduced the enhancing effects of miR-21 on cell proliferation. Therefore, GABPB1‑IT1 may upregulate PTEN by sponging miR-21 in ccRCC to inhibit cancer cell proliferation. Our study characterized a novel GABPB1‑IT1/miR-21/PTEN axis in ccRCC.     

Delivery of microRNA-21-sponge and pre-microRNA-122 by MS2 virus-like particles to therapeutically target hepatocellular carcinoma cells

MicroRNAs are related to the development of hepatocellular carcinoma and can serve as potential therapeutic targets. Therapeutic strategies increasing tumor-suppressive microRNAs and reducing oncogenic microRNAs have been developed. Herein, the effects of simultaneously altering two microRNAs using MS2 virus-like particles were studied. The sequences of microRNA-21-sponge and pre-microRNA-122 were connected and cloned into a virus-like particle expression vector. Virus-like particles containing microRNA-21-sponge and pre-microRNA-122 sequences were prepared and crosslinked with a cell-specific peptide targeting hepatocellular carcinoma cells. Delivery effects were studied using RT-qPCR and functional assays to investigate the level of target mRNAs, cell toxicity, and the effects of proliferation, invasion, and migration. Virus-like particles delivered miR-21-sponge into cells, with the Ct value reaching 10 at most. The linked pre-miR-122 was processed into mature miR-122. The mRNA targets of miR-21 were derepressed as predicted and upregulated 1.2–2.8-fold, and the expression of proteins was elevated correspondingly. Proliferation, migration, and invasion of HCC cells were inhibited by miR-21-sponge. Simultaneous delivery of miR-21-sponge and miR-122 further decreased proliferation, migration, and invasion by up to 34%, 63%, and 65%, respectively. And the combination promoted the apoptosis of HCC cells. In conclusion, delivering miR-21-sponge and miR-122 using virus-like particles modified by cell-specific peptides is an effective and convenient strategy to correct microRNA dysregulation in hepatocellular carcinoma cells and is a promising therapeutic strategy for hepatocellular carcinoma.     

microRNA-21在食管癌细胞增殖、迁移和凋亡中的作用

本研究检测了40例食管癌组织和40例癌旁组织中的miR-21、PTEN、PI3K和AKT表达,并通过转染miR-21抑制剂来敲低人食管癌细胞系EC9706的miR-21表达,考察了miR-21对食管癌细胞生长的影响。研究发现,食管癌组织中PTEN蛋白的阳性染色评分低于癌旁组织(p<0.05),而PI3K和AKT蛋白的阳性染色评分高于癌旁组织(p<0.05)。miR-21在人食管癌组织中被上调(3.56 vs 1.21,p<0.05)。转染miR-21抑制剂导致PTEN蛋白表达升高,而PI3K和AKT蛋白表达降低(p<0.05)。转染miR-21抑制剂抑制了EC9706细胞的增殖和迁移,但促进了细胞凋亡(p<0.05)。miR-21的上调可通过激活PTEN/PI3K/AKT信号通路来促进食道癌细胞的增殖和迁移,并抑制细胞凋亡。     

Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer

Trastuzumab resistance emerges to be a major issue in anti-human epidermal growth factor receptor 2 (HER2) therapy for breast cancers. Here, we demonstrated that miR-21 expression was up-regulated and its function was elevated in HER2(+) BT474, SKBR3, and MDA-MB-453 breast cancer cells that are induced to acquire trastuzumab resistance by long-term exposure to the antibody, whereas protein expression of the PTEN gene, a miR-21 target, was reduced. Blocking the action of miR-21 with antisense oligonucleotides re-sensitized the resistant cells to the therapeutic activities of trastuzumab by inducing growth arrest, proliferation inhibition, and G(1)-S cell cycle checking in the presence of the antibody. Ectopic expression of miR-21 in HER2(+) breast cancer cells confers resistance to trastuzumab. Rescuing PTEN expression with a p3XFLAG-PTEN-mut construct with deleted miR-21 targeting sequence at its 3' UTR restored the growth inhibition of trastuzumab in the resistant cells by inducing PTEN activation and AKT inhibition. In vivo, administering miR-21 antisense oligonucleotides restored trastuzumab sensitivity in the resistant breast cancer xenografts by inducing PTEN expression, whereas injection of miR-21 mimics conferred trastuzumab resistant in the sensitive breast tumors via PTEN silence. Up-regulatin of miR-21 in tumor biopsies obtained from patients receiving pre-operative trastuzumab therapy was associated with poor trastuzumab response. Therefore, miR-21 overexpression contributes to trastuzumab resistance in HER2(+) breast cancers and antagonizing miR-21 demonstrates therapeutic potential by sensitizing the malignancy to anti-HER2 treatment.     

MEG3 interacted with miR-494 to repress bladder cancer progression through targeting PTEN

The long noncoding RNA MEG3 is a significant tumor-suppressive gene in various tumors. But its biological role in bladder cancer remains uninvestigated. Herein, the biological mechanism of MEG3 in bladder cancer pathogenesis was explored. First, the expression of MEG3 in bladder cancer cells was examined, and we found that it was significantly reduced. In addition, in bladder cancer cells, we observed htat miR-494 was increased. Then, MEG3 was overexpressed in UMUC3 and SW780 cells and it could negatively modulate miR-494 expression. Bladder cancer cell proliferation was repressed, cell apoptosis was triggered and meanwhile, the cell cycle was remarkably arrested by the overexpression of MEG3. Moreover, the increase of MEG3 suppressed bladder cancer cell migration and invasion capacity. MEG3 can sponge miR-494 and the binding sites between them were confirmed by carrying out a series of functional assays. Furthermore, PTEN was speculated as a putative target of miR-494. Meanwhile, we found that miR-494 inhibitors induced PTEN. Finally, in vivo assays were conducted to prove that MEG3 can restrain bladder tumor growth by modulating miR-494 and PTEN. In conclusion, it was suggested MEG3 can interact with miR-494 to regulate PTEN in bladder cancer development.     

Dissimilar microRNA-21 functions and targets in trophoblastic cell lines of different origin

Trophoblast cells express a singular miRNA expression profile which varies during pregnancy and whose alteration may be associated with pregnancy complications. miR-21, a widely known oncomir, is highly expressed in human placenta but its role in regulating trophoblast cells remains unclear. The aim of this study was to investigate miR-21 functions and targets in HTR-8/SVneo immortalized trophoblast and JEG-3 choriocarcinoma cells, which are trophoblast cell models that differ in their cellular origin. Cells were transfected with miR-21-antagomir, -mimic or their respective controls. Following, cell proliferation (BrdU), migration (Transwell and scratch wound-healing assays), invasion (Matrigel assays) and apoptosis (flow cytometry, TUNEL assay and Western blotting) were assessed. Expression of the potential miR-21 targets phosphatase and tensin homolog (PTEN) and programmed cell death 4 (PDCD4) were analyzed by Western blotting. Inhibition of miR-21 decreased cell proliferation, migration, and invasion in JEG-3 and HTR-8/SVneo cells and additionally, induced apoptosis in JEG-3 cells. Silencing of miR-21 enhanced PDCD4 expression only in JEG-3 cells, and PTEN expression only in HTR-8/SVneo cells. Inhibition of miR-21 significantly increased phosphorylation of AKT in HTR-8/SVneo cells. In conclusion, miR-21 has cell-specific targets depending upon the origin of trophoblastic cells. Furthermore, miR-21 regulates major cellular processes including cell growth, migration, invasion and apoptosis suggesting that its impairment may lead to placental disorders.     

MicroRNA-590-5p regulates proliferation and invasion in human hepatocellular carcinoma cells by targeting TGF-β RII

MicroRNAs (miRNAs) are regulatory small non-coding RNAs that can regulate gene expression by binding to gene elements, such as the gene promotor 5'UTR, mainly in the 3'UTR of mRNA. One miRNA targets many mRNAs, which can be regulated by many miRNAs, leading to a complex metabolic network. In our study, we found that the expression level of miR-590-5p is higher in the human hepatocellular carcinoma cell line HepG2 than in the normal hepatocellular cell line L02. Downregulation of miR-590-5p inhibited proliferation and invasion of hepatocellular carcinoma cells (HCCs). We also showed that expression of TGF-beta RII, which has been regarded as a regulator of tumor proliferation, invasion, and migration in hepatocellular carcinoma, is regulated by miRNA-590-5p. In addition, miR-590-5p downregulated the expression of TGF-beta RII by targeting the 3'UTR of mRNA. We also found that downregulation of miR-590-5p was associated with an elevation of TGF-beta RII and inhibition of proliferation and invasion in HepG2 cells. Furthermore, overexpression of miR-590-5p was associated with upregulation of TGF-beta RII and could promote proliferation and invasion in L02 cells. In conclusion, we determined that TGF-beta RII is a novel target of miRNA-590-5p. Thus, the role of TGF-beta RII in regulating proliferation and invasion of human HCCs is controlled by miR-590-5p. In other words, miR-590-5p promotes proliferation and invasion in human HCCs by directly targeting TGF-beta RII.